Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?

Key Takeaways Incyte (INCY) has put up a good performance in the past three months. Shares of the company have gained 9.2% against the industry's decline of 1.3%. The stock has also outperformed the sector in the said timeframe. INCY Outperforms Industry & Sector The outperformance can be attributed to positive pipeline and regulatory updates. Lead drug Jakafi (ruxolitinib) also maintains momentum. Let us take a look at what's happening with Incyte. Pipeline/Regulatory Updates Boost INCY Stock Last month, t ...